^
    Back
    Association details:
    Biomarker:PD-L1 overexpression
    Cancer:Non Small Cell Lung Cancer
    Regimen: (cisplatin + gemcitabine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    ESMO 2020
    Title:

    1370P - PD-L1 expression as a predictive biomarker for chemotherapy response in metastatic non-small cell lung cancer (mNSCLC)

    Published date:
    09/14/2020
    Excerpt:
    Twelve trials were identified, involving 4031 patients with EGFR/ALK wild type tumors…Chemotherapy consisted of a cisplatin/carboplatin backbone with pemetrexed/gemcitabine/nab-paclitaxel...High PD-L1 expression is associated with improved ORR with platinum doublet chemotherapy in mNSCLC.